test 1

Onco

United States

Late-Stage Active Oncology Drug Developers | An Overview

June 22, 2024

NK is the abbreviation of Natural Killer, and its Chinese name is natural killer cell. Due to the pan-specific...

United States

South America – Early-Stage Active Oncology Drug Developers

March 9, 2023

United States

Australia & New Zealand – Early-Stage Active Oncology Drug Developers

March 9, 2023

United States

South Korea – Early-Stage Active Oncology Drug Developers | Asia (Part 4)

March 9, 2023

United States

Early-Stage Active Oncology Drug Developers | An Overview

March 9, 2023

United States

China – Early-Stage Active Oncology Drug Developers | Asia (Part 1)

March 9, 2023

Onco

United States

Late-Stage Active Oncology Drug Developers | An Overview

June 22, 2024

NK is the abbreviation of Natural Killer, and its Chinese name is natural killer cell. Due to the pan-specific...

United States

South America – Early-Stage Active Oncology Drug Developers

March 9, 2023

United States

Australia & New Zealand – Early-Stage Active Oncology Drug Developers

March 9, 2023

United States

South Korea – Early-Stage Active Oncology Drug Developers | Asia (Part 4)

March 9, 2023

United States

Early-Stage Active Oncology Drug Developers | An Overview

March 9, 2023

United States

China – Early-Stage Active Oncology Drug Developers | Asia (Part 1)

March 9, 2023

test 1

Onco

Late-Stage Active Oncology Drug Developers | An Overview

South America – Early-Stage Active Oncology Drug Developers

Australia & New Zealand – Early-Stage Active Oncology Drug Developers

South Korea – Early-Stage Active Oncology Drug Developers | Asia (Part 4)

Early-Stage Active Oncology Drug Developers | An Overview

China – Early-Stage Active Oncology Drug Developers | Asia (Part 1)

Onco

Late-Stage Active Oncology Drug Developers | An Overview

South America – Early-Stage Active Oncology Drug Developers

Australia & New Zealand – Early-Stage Active Oncology Drug Developers

South Korea – Early-Stage Active Oncology Drug Developers | Asia (Part 4)

Early-Stage Active Oncology Drug Developers | An Overview

China – Early-Stage Active Oncology Drug Developers | Asia (Part 1)

Mapping Bio-Innovations

Approved Monoclonal Antibodies for Cancer Treatment

Approved Oncology Targeting Small Molecule Kinase Inhibitors

Early-Stage Cancer Drug Developers Developing Kinase Inhibitors – 2023

Kinase Inhibitors in Preclinical Development – 2021

Early-Stage Cancer Drug Developers Developing Kinase Inhibitors – 2023

Hoffmann-La Roche –
Oncology Drug Pipeline Insights – June 2021

AbbVie, Inc. –
Oncology Drug Pipeline Insights – June 2021

Amgen, Inc.
Oncology Drug Pipeline Analysis – June 2021

Late-Stage Active Oncology Drug Developers | An Overview

South America – Early-Stage Active Oncology Drug Developers

Australia & New Zealand – Early-Stage Active Oncology Drug Developers

South Korea – Early-Stage Active Oncology Drug Developers | Asia (Part 4)

Welcome Back!

Create New Account!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?